Abstract: In this study, plaque reduction neutralization assays demonstrated that mAb 1741-LALA neutralizes SARS-CoV-2 strains B.1.351, D614 and D614G.
Abstract: MAbs S1D2-hIgG1 and S1D2-LALA mutant (STI-1499-LALA) did not neutralize B.1.351, but did neutralize SARS-CoV-2 strains D614 and D614G.
Conclusion: In this study, clone 1741-LALA showed a broad neutralizing activity against SARS-CoV-2 D614G and B.1.351 variants, suggesting this mAb may protect against other SARS-CoV-2 variants.
Introduction: Clones STI-1499-LALA and S1D2-hIgG1 did not neutralize B.1.351, but did neutralize strains D614 and D614G.
Introduction: Our plaque reduction neutralization assays demonstrate that clone 1741-LALA neutralizes SARS-CoV-2 strains B.1.351, D614, and D614G.
Result: For strain
SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response.
PMID: 34639178
2021
International journal of molecular sciences
Discussion: An engineered ACE2-rigid-foldon, as a trimeric protein (PDB 7CT5) inhibits eight naturally occurring mutants, including D614G and seven other RBD domain mutants.
Discussion: As a result, the energy barrier for the conformational change is reduced and SARS-CoV-2 D614G strains have increased sensitivity to the presence of hACE2, which could be the underlying mechanism for enhanced infectivity observed in these strains.
Discussion: As such, it is hypothesised that the Delta variant emerged mainly as a result of reduced immune recognition and enhanced transmissibility nonrelated with affinity (effects from mutations D614G, P681 and D950N).
Discussion: From all the mutations in prevalent variants by June 2021 worldwide, mutation D614G is the only one located
Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies.
Discussion: However, L452R is a spike mutation of interest (MOI) present in the VOC lineages B.1.427/B.1.429 (reported in California, USA, on 09/20, now Epsilon), B.1.526.1 (New York City, USA, 10/20, Iota subtype), and in the B1.617.1 (Kappa)/B.1.617.2 (Delta)/B.1.617.3 lineages now rapidly and deadly spreading in India (12/20-02/21), where it is always found along with the D614G substitution.
Discussion: In parallel, the titer neutralizing antibodies induced by the m-RNA vaccines approved by both governmental agencies (i.e., the BNT162b2 Pfizer/BioNTech COVID-19 vaccine/Comirnaty and COVID-19 vaccine Moderna) against the same SARS-CoV-2 variant is reported to decline by 7- to 12 -fold, while no negative effect on neutralization is seen for the B.1.1.7 (Alpha) variant (with N501
Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
Discussion: After the onset of the SARS-CoV-2 outbreak, the D614G strain rapidly replaced the original virus strain and became the dominant variant.
Discussion: Further studies showed that the host cell infectivity of D614G was increased, compared with the original virus, because of mutation-related structure changes.
Discussion: However, neutralization analyses of convalescent sera from D614G-, B.1.1.7- and B.1.351-infected patients indicate that B.1.351 variant induced much lower antibody production, compared with other variants.
Discussion: Slightly enhancements of infectivity were observed among most of the tested variants, compared with the D614G reference strain, whereas the B.1.1.298 variants (mink cluster 5) displayed significantly decreased infectivity.
Discussion: When TMPRSS2 overexpressed infection was compared to m
Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.
PMID: 34648284
2021
Journal of chemical information and modeling
Result: All three recombinant viruses, including the wild type SARS-CoV-2-WA1/2020 (the first isolate reported in the U.S.) and mutants with L452R/E484Q/D614G or
Figure: (a) LY-CoV555 of different concentrations was added to pseudovirions bearing the wild type Wuhan-Huh-1 spike or sequences containing triple mutations found in the Kappa variant (L452R/E484Q/D614G).
Figure: (b) Plaque reduction neutralization assays were performed to evaluate the neutralizing ability of LY-CoV555 against WA1/2020, recombinant virus containing L452R/E484Q/D614G or E484Q/D614G.
In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential.
Introduction: For example, the D614G mutation displayed heightened infectivity and quickly became the most prevalent form spreading early in the COVID-19 pandemic.
Result: A baseline RLU for primary infection with N501Y + D614G or N501Y + K417N + E484K + D614G PsV was set as the average RLU of 10 mice infected with the respective PsV.
Result: All groups were then challenged with N501Y + D614G VSV PsV.
Result: Although the same titer trends remained for WT IgG RBD-directed responses compared with anti-spike, significant ablation of binding was obser
Genomic reconstruction of the SARS-CoV-2 epidemic in England.
Result: Since the dominant S sequence variant seen in clinical isolates is D614G, all the SARS-CoV-2 pseudovirus variants we constructed were coupled with the D614G variant.
The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil.
Method: Next, in the set of genomes found, we verified all mutations, excluding those that define the B.1.1.28 lineage (C241T, F924F, P4715L, D614G, V1176F, R203K, R203R and G204R).
SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
Introduction: In addition, the SARS-CoV-2 viral variants carrying P323L mutation in NSP12 and the associated D614G mutation in spike protein were reported to be enriched in severely affected group.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Antiviral research
Browser Board
Co-occurred Entities
Filtrator
ViMRT